ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Sheet 1 of 10

Form PTO-1449 **U.S. Department of Commerce** **Information Disclosure Statement**	**DOCKET NO.** 046483-6001US11(00853)	**APPLN. NO.** To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	**GROUP:** Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
		5,359,046	10/25/1994	Capon et al.			
		5,686,281	11/11/1997	Roberts			
		5,712,149	01/27/1998	Roberts			
		5,874,240	02/23/1999	Ni et al.			
		5,906,936	05/25/1999	Eshhar, et al.			
		6,103,521	08/15/2000	Capon et al.			
		6,319,494	11/20/2001	Capon et al.			
		6,355,779	03/12/2002	Goodwin et al.			
		6,410,319	06/25/2002	Raubitschek, et al.			
		US2003/060444	03/27/2003	Finney et al.			
		US2003/0077249	04/24/2003	Bebbington et al.			
		6,569,997	05/27/2003	Kwon			
		US2003/0148982	08/07/2003	Brenner et al.			
		US2004/038886	02/26/2004	Finney et al.			
		US2004/0043401	03/04/2004	Sadelain, et al.			
		US2005/0113564	05/26/2005	Campana, et al.			
		US2005/0129671	06/16/2005	Cooper et al.			
		7,049,136	05/23/2006	Seed et al.			
		7,052,906	05/30/2006	Lawson et al.			
		7,070,995	07/04/2006	Jensen			
		7,265,209	09/04/2007	Jensen			
		7,319,143	01/15/2008	Gross, et al.			
		7,320,787	01/22/2008	Seed et al.			
		US2008/0131415	06/05/2008	Riddell et al.			

Examiner Signature:	**Date Considered:**
/Michael Burkhart/	02/17/2016

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Form PTO-1449 **U.S. Department of Commerce** **Information Disclosure Statement**	**DOCKET NO.** 046483-6001US11(00853)	**APPLN. NO.** To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	**GROUP:** Not Yet Assigned

		7,446,190	11/04/2008	Sadelain, et al.			
		7,446,191	11/04/2008	Jensen			
		7,514,537	04/07/2009	Jensen			
		US2009/0257994	10/15/2009	Jensen			
		7,741,465	06/22/2010	Eshhar et al.			
		US2010/0233200	09-16-2010	Medin			
		US2011/0052554	03/03/2011	Zakrzewski et al.			
		7,994,298	08/09/2011	Zhang et al.			
		US2012/0148552	06/14/2012	Jensen			
		8,211,422	07/03/2012	Esshar et al.			
		8,252,914	08/28/2012	Zhang et al.			
		8,389,282	03/05/2013	Sadelain et al.			
		8,399,645	03/19/2013	Campana et al.			
		US2013/071414	03/21/2013	Dotti et al.			
		8,465,743	06/01/2013	Rosenberg, et al.			
		US2013/0149337	06/13/2013	Cooper, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract
		WO1992/015322	17 Sep 1992	PCT			
		WO/1995/30014	09 Nov 1995	PCT			
		WO1996/23814	08 Aug 1996	PCT			
		WO1996/24671	15 Aug 1996	PCT			
		WO/1997/015669	01 May 1997	PCT			
		WO/1997/23613	03 Jul 1997	PCT			
		WO1998/18809	07 May 1998	PCT			
		WO1999/00494	07 Jan 1999	PCT			

Examiner Signature:	**Date Considered:**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Sheet 3 of 10

Form PTO-1449 **U.S. Department of Commerce** **Information Disclosure Statement**	**DOCKET NO.** 046483-6001US11(00853)	**APPLN. NO.** To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	**GROUP:** Not Yet Assigned

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract
		WO1999/57268	11 Nov 1999	PCT			
		WO/2000/14257	16.03.2000	PCT			
		WO/2002/077029	03 Oct 2002	PCT			
		WO/2002/033101	25 Apr 2002	PCT			
		WO/2002/088334	07 Nov 2002	PCT			
		EP 0574512B1	05 Feb 2003	EP			
		EP1226244	28 July 2004	EP			
		WO2005/019429	03 Mar 2005	PCT			
		EP871495	15 June 2005	EP			
		WO2006/060878	15 Jun 2006	PCT			
		WO2008/045437	17 Apr 2008	PCT			
		WO2009/091826	23 Jul 2009	PCT			
		WO/2010/025177	04 Mar 2010	PCT			
		WO/2010/085660	29 Jul 2010	PCT			
		WO2011/059836	19 May 2011	PCT			
		WO2012/033885	15 Mar 2012	PCT			
		WO2012/058460	03 May 2012	PCT			
		WO2012/082841	21 Jun 2012	PCT			
		WO2012/127464	27 Sep 2012	PCT			
		WO2012/135854	04 Oct 2012	PCT			
		WO2012/138858	11 Oct 2012	PCT			
		WO2013/033626	07 Mar 2013	PCT			
		WO2013/040371	21 Mar 2013	PCT			
		WO2013/059593	25 Apr 2013	PCT			

Examiner Signature:	**Date Considered:**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Sheet 4 of 10

Form PTO-1449 **U.S. Department of Commerce** **Information Disclosure Statement**	**DOCKET NO.** 046483-6001US11(00853)	**APPLN. NO.** To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	**GROUP:** Not Yet Assigned

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract
		WO 2001/34843	17 May 2001	PCT			English equivalent of JP2003-517301
		JP2003-517301	27 May 2003	JP			Yes
		WO 02/077029	03 Oct 2002	PCT			English equivalent of JP2004-529636
		JP2004-529636	30 Sep 2004	JP			Yes

OTHER DOCUMENT(S) (*Including Author, Title, Date, Pertinent Pages, etc.*)		
		A NCBI Direct Submission NP 000725 dated November 21, 2010
		A NCBI Direct Submission NP 932170.1 dated November 21, 2010
		Baeksgaard et al., "Acute tumor lysis syndrome in solid tumors--a case report and review of the literature." 2003, Cancer Chemother Pharmacol., 51:187-92
		Bondanza et al., "Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes." 2006, Blood 107:1828-1836
		Brentjens et al., "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15." 2003, Nature Medicine, 9(3): 279-286
		Brentjens et al., "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts." 2007, Clin Cancer Res 13:5426-5435
		Brentjens et al., "Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias." 2011 Blood 118(18):4817-4828
		Brentjens et al., "Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial." 2010, Mol Ther, 18: 666-8
		Brentjens, et al. "A Phase I Trial for the Treatment of Chemo-refractory Chronic Lymphocytic Leukemia with CD19-Targeted Autologous T Cells." Mol. Therapy, 2008, p. S15, Vol 16, Suppl 1.
		Brocker and Karjalainen, "Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes." 1995, J. Exp. Med., 181:1653-1659
		Call, et al., "The T cell receptor: critical role of the membrane environment in receptor assembly and function." 2005, Annu Rev Immunol. 2005, 23:101-125
		Campana et al., "T-Cell Immunotherapy for B-Lineage Acute Lymphoblastic Leukemia Using Chimeric Antigen Receptors That Deliver 4-1BB-Mediated Costimulatory Signals" 2003 Blood 102(11); abstract #223
		Carpenito et al., "Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains." 2009, Proc Natl Acad Sci U S A 106:3360-3365

Examiner Signature:	**Date Considered:**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

Sheet 5 of 10		
Form PTO-1449 **U.S. Department of Commerce** **Information Disclosure Statement**	**DOCKET NO.** 046483-6001US11(00853)	**APPLN. NO.** To Be Assigned
	APPLICANT: Carl H. June et al.	
	FILING DATE: Herewith	**GROUP:** Not Yet Assigned

		OTHER DOCUMENT(S) (*Including Author, Title, Date, Pertinent Pages, etc.*)
		Davila et al., "B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen." 2010 ASH Meeting Abstract No. 3268, presented December 6, 2010 (poster abstract)
		Davila et al., "T Cells Genetically Targeted to CD19 Eradicate B-All in a Novel Syngeneic Mouse Disease Model." 2010 ASH Meeting Abstract No. 171, presented December 6, 2010 (poster abstract)
		Dohner et al., "p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias." 1995, Blood, 85: 1580-9
		Dropulic et al., "Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome." 2006, Human Gene Therapy, 17: 577-88
		Dull et al., "A third-generation lentivirus vector with a conditional packaging system." 1998, J Virol, 72: 8463-71
		Eshhar et al., "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the Yor ζ subunits of the immunoglobulin and T-cell receptors." 1993, Proc Natl Acad Sci USA 90:720-724
		Finney et al., "Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 (4-1BB) in series with signals from the TCR zeta chain." 2004, J. Immunol 172:104-113.
		Finney et al., "Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product." 1998, J Immunol 161:2791-2797
		Friedmann-Morvinski et al., "Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation." 2005, Blood 105:3087-3093
		Geiger and Jyothi, "Development and application of receptor-modified T lymphocytes for adoptive immunotherapy." 2001, Transfusion Medicine Reviews, 15(1): 21-34
		Geiger et al., "Integrated src kinase and constimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes," 2001, Blood 98(8):2364-71
		Gilham et al., "Primary Polyclonal Human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3ζ- based chimeric immune receptors." 2001, J. Immunology, 25(2): 139-151
		Gong et al., "Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate=specific membrane antigen." 1999, Neoplasia, 1(2): 123-127
		Gribben et al., "Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia." 2011, Biol Blood Marrow Transplant, 17: Suppl:S63-S70
		Griffin et al., "Development and application of surface-linked single chain antibodies against T-cell antigens." 2001, J. Immunological Methods, 248: 77-90
		Gross and Eshhar, 1992, "Endowing T cells with antibody specificity using chimeric T cell receptors." 1992, FASEB J. 6: 3370-3378
		Hallek et al., "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines." 2008, Blood 111(12):5446–5456

Examiner Signature:	**Date Considered:**

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.